In a recent development, shares of Acadia Pharmaceuticals Inc. experienced a 15% drop in the extended session on Monday. This sudden decline was prompted by news that one of the pharma company's drugs failed to achieve the desired outcomes in a late-stage trial related to schizophrenia treatment.
Disappointing Results for Pimavanserin
Acadia's pimavanserin, known as Nuplazid in the market, fell short of demonstrating a statistically significant improvement over a placebo in alleviating certain symptoms of schizophrenia, as confirmed by the company itself. Despite the drug's long-standing presence in the market and FDA approval for addressing hallucinations and delusions linked to Parkinson's disease psychosis, it did not meet expectations in this specific trial.
CEO Expresses Disappointment
Expressing his disappointment, Acadia's Chief Executive, Steve Davis, shared his sentiments in a statement. He emphasized the significant unmet needs of patients grappling with negative symptoms of schizophrenia, underscoring the letdown caused by the trial results.
Future Plans and Market Comparison
While Acadia plans to conduct further analysis of the data from the study, no additional clinical trials involving pimavanserin are currently on the horizon. Over the past year, Acadia's shares have seen an 18% increase, although this pales in comparison to the 33% gains observed in the S&P 500 index.
Tesla Stock Trends Update
Our Latest News
Revisions to U.K. Growth Data Spark Investor Interest
Revised U.K. growth data challenges previous perceptions, revealing a more positive outlook and attracting investor interest. Explore the potential for diversif...
Auto-Parts Suppliers at Risk of UAW Strike Impact
The risk faced by auto-parts suppliers in the event of a UAW strike and the potential impact on the supply chain. Lear Corp., Magna International Inc., Aptiv Pl...
Industrial and Transportation Stocks Volatile After Q3 Earnings
Shares in the industrial and transportation sectors experienced volatility after Q3 earnings reports. Boeing registered a loss, General Dynamics delivered stron...